Cardiol Therapeutics Inc. (CT9.F)
- Previous Close
1.6220 - Open
1.6320 - Bid 1.6160 x --
- Ask 1.6840 x --
- Day's Range
1.6320 - 1.6320 - 52 Week Range
0.4920 - 1.9100 - Volume
2,000 - Avg. Volume
1,373 - Market Cap (intraday)
114.146M - Beta (5Y Monthly) 0.71
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3000 - Earnings Date May 17, 2024 - May 21, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.
www.cardiolrx.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: CT9.F
Performance Overview: CT9.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CT9.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CT9.F
Valuation Measures
Market Cap
114.15M
Enterprise Value
90.43M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
5.78
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.06
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-37.71%
Return on Equity (ttm)
-69.93%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-28.13M
Diluted EPS (ttm)
-0.3000
Balance Sheet and Cash Flow
Total Cash (mrq)
34.93M
Total Debt/Equity (mrq)
0.62%
Levered Free Cash Flow (ttm)
-14.99M
Company Insights: CT9.F
CT9.F does not have Company Insights